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Available online 7 March 2015AbstractChronic prostatitis is a heterogeneous condition with high prevalence rate. Chronic prostatitis has overlap in clinical presentation with other
prostate disorders and is one of the causes of high serum prostate specific antigen (PSA) level. Chronic prostatitis, unlike acute prostatitis, is
difficult to diagnose reliably and accurately on the clinical grounds alone. Not only this, it is also challenging to differentiate chronic prostatitis
from prostate cancer with imaging modalities like TRUS and conventional MR Imaging, as the findings can mimic those of prostate cancer. Even
biopsy doesn't play promising role in the diagnosis of chronic prostatitis as it has limited sensitivity and specificity. As a result of this, chronic
prostatitis may be misdiagnosed as a malignant condition and end up in aggressive surgical management resulting in increased morbidity. This
warrants the need of reliable diagnostic tool which has ability not only to diagnose it reliably but also to differentiate it from the prostate cancer.
Recently, it is suggested that multiparametric MR Imaging of the prostate could improve the diagnostic accuracy of the prostate cancer. This
review is based on the critically published literature and aims to provide an overview of multiparamateric MRI techniques in the diagnosis of
chronic prostatitis and its differentiation from prostate cancer.
© 2015 Beijing You’an Hospital affiliated to Capital Medical University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction specific physical findings or diagnostic laboratory tests to di-Prostatitis is one of the common reasons why patients visit
physicians and urologists. The prevalence of prostatitis is high,
overall rate of 8.2%, which is comparable to rates of ischemic
heart disease and diabetes [1]. This necessitates the need for
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the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).agnose it. The National Institute of Health (NIH) established
an International Prostatitis Collaborative Network (IPCN) and
came with 4 categories of prostatitis syndromes viz. I) Acute
bacterial prostatitis, II) Chronic bacterial prostatitis, III)
Chronic non-bacterial prostatitis/Chronic pelvic pain syn-
drome (CP/CPPS) which was further categorized into in-
flammatory (category IIIA) and non-inflammatory (category
IIIB), IV) Asymptomatic inflammatory prostatitis [1]. Acute
and chronic bacterial prostatitis are best understood among
them and are easier to diagnose clinically. Chronic nonbac-
terial prostatitis is the most common and affect 10e15% of
male population [2], however, remains the diagnosis of
exclusion. The working diagnostic criteria that is used clini-
cally is the presence of pelvic pain or urinary symptoms for
more than three of the previous 6 months with no evidence of. Production and hosting by Elsevier B.V. This is an open access article under
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[2]. Chronic prostatitis can be a cause of elevated prostate
specific antigen (PSA) level. This warrants further in-
vestigations as the elevated PSA level should not be attributed
to chronic prostatitis without ruling out prostate cancer [3,4].
The current emphasis is on the studies that provide indirect
information about the prostate like DRE, Retrograde ure-
thrography, Cystourethroscopy [5]. The reliable and accurate
diagnosis has yet been difficult to achieve due to the hetero-
geneous nature of chronic prostatitis. MRI provides visuali-
zation of the interior structure and better delineation of anatomy
and prostate pathologic condition. TRUS, CT and conventional
MRI are informative but it is difficult to detect and differentiate
chronic prostatitis from prostate cancer with these radiological
modalities as the findings can mimic those of prostate cancer
[6e8]. Multiparametric MRI is better at detecting the prostate
cancer with high sensitivity and specificity [9,10]. Multi-
parametric MRI is also helpful in predicting the presence of
prostate cancer in prostate biopsy [11]. It is also helpful in
differentiating of prostatitis and prostate cancer [12].
2. Anatomy relevant to chronic prostatitis
MRI is superior to CT, ultrasound or other radiological
modalities in delineating the anatomy of prostate and its sur-
roundings. Prostate is a walnut shaped gland, which sits on the
urogenital diaphragm in the lower pelvis just inferior to the
urinary bladder (Figs. 1 and 2). The anterior wall is separated
from the pubic bone by the retropubic fatty space of Retzius.
The posterior wall is separated from the rectal ampulla by
Denonvillier's fascia. The fluid filled seminal vesicles are sit-
uated postero-superior lying between the bladder and the
rectum (Fig. 2B). The ejaculatory duct, which is formed after
the seminal duct joins the ductus deference, enters the prostate
gland posteriorly, runs into it and finally opens on the seminal
colliculus (verumontanum) at the utricle of the prostatic ure-
thra. Neurovascular bundles, responsible for erection of theFig. 1. Axial T2WI showing the zonal anatomy of the prostate. The central
gland (C) is shown as heterogeneous signal intensity surrounded by a crescent
shaped hyperintense peripheral zone (P) on both sides.penis, run from superior to inferior in the posterolateral sides
of the prostate glands. The prostate gland is divided into base,
mid-prostate and apex from superior to inferior (Fig. 2B).
The prostate is divided anatomically into three zones viz.
the peripheral, the transition and the central zones (Figs. 1 and
2). Anterior fibromuscular stroma, mainly consisting of
muscular and the connective tissue and lacking glandular tis-
sue, is located in the anterior part of the prostate gland. The
peripheral zone of the prostate is situated postero-inferiorly
and is the most common location for malignancy, around
70e80% of the prostate cancer foci being located in this zone
[13,14]. Located interiorly and surrounding the prostatic ure-
thra is the transition zone and postero-superior to it is the
central zone. Transition zone is common site for benign
prostatic hyperplasia (BPH). The transition and the central
zones are together called as internal or central gland, as they
are barely distinguishable from one another [15]. Due to the
occurrence of benign prostatic hyperplasia with increasing
age, the morphology of central gland changes from central
zone into transition zone. As nodules in the transition zone
advances, the central zone undergoes compression with pro-
gressive displacement towards the prostatic base which makes
anatomy of the central zone difficult to be defined with con-
fidence by MR Imaging [16] (Fig. 1). Around 20% and 10% of
the prostate cancer foci arise from the transition and the
central zone, respectively [17]. Chronic prostatitis main-
lyoccursin the peripheral zone of prostate and is more
demonstrable than acute condition in the context of MRI ex-
amination. Chronic prostatitis can be present with symptoms
of benign prostatic hyperplasia (BPH). It is also commonly
associated with elevated serum prostate specific antigen
(PSA). Therefore, it is an important differential in the diag-
nosis of prostate cancer.
3. MR examinations
Multiparametric prostate MR examination combines both
conventional as well as functional MR imaging, and requires
at least16 channel1.5 T with endorectal coil or 3.0 T with or
without endorectal coil. 3.0 T image acquisition provides
better signal-to-noise ratio (SNR) with faster acquisition of
high quality image, with or without the use of endorectal coil
[18]. However, the longer T1 and shorter T2 relaxation times
are the disadvantages with higher field strength of 3.0 T [19].3.1. T2 weighted MR imagingT2WI MR Images are used to show anatomy of the prostate
and its surrounding structures. The normal appearance of the
peripheral zone of the prostate gland is characterized by the
homogenous intermediate to high intensity signal (Fig. 3A).
The peripheral zone is surrounded by capsule represented as a
thin hypointense rim on MR image, which clearly depicts it
from the transition and central zone. Lesions of chronic
prostatitis, on T2WI MR imaging, usually present with uni-
lateral or bilateral diffuse or flaky areas with little to no mass
effect or wedge shaped areas of low signal intensity in the
Fig. 2. (A) Coronal T2WI and (B) sagittal T2WI showing cranio-caudal segmentation of the prostate and its surrounding structures. B ¼ Base, M ¼ Mid-prostate,
A ¼ Apex, SV ¼ Seminal Vesicles.
Fig. 3. Multiparametric MR images of a normal prostate. The peripheral zone shows the high signal intensity on the T2WI and ADC map. The MRS images shows
prominent citrate peak at a frequency of 2.6 ppm and choline peak at 3.2 ppm. (A) Axial T2WI, (B) Axial DWI, (C) Axial ADC, (D) MRS, (E) MRS biochemical
parameter. Cr. ¼ Creatinine, Cho. ¼ Choline, Ci. ¼ Citrate.
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other benign condition like scar tissue, atrophy, post radiation
changes and hormonal treatment effect also often present as a
region of low signal intensity on T2WI MR Images [20,21].Fig. 4. Multiparametric MR images at 3.0 Twithout endorectal coils of a 62 years m
Axial T2WI MR Image shows low signal intensity area in peripheral zone predom
zone. (B) Axial DWI and (C) Axial ADC map shows corresponding area of high s
diffusion, indicative of tumor. (D) Axial gadolinium based DCE image shows area
Curve of the DCE image shows rapid early enhancement with subsequent washo
elevated choline and creatine peaks with reduced citrate and (G) Value of MRS show
(H) Histopathology slide confirms the diagnosis.The lesion which shows low T2 signal intensity with ill-
defined border from the normal part of the peripheral zone
of the prostate and the swollen surface but without capsular
breach of the organ is interpreted as benign inflammatoryan showing a typical case of prostate cancer located in the peripheral zone. (A)
inantly in the right and extending across the midline to left medial peripheral
ignal intensity and low signal intensity, respectively consistent with restricted
of early enhancement within corresponding area of restricted diffusion and (E)
ut (type IV curve), consistent with tumorous lesion. (F) MRS Image shows
s the elevated Cho þ Cr/Ci, further supporting the diagnosis of prostate cancer.
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effect or wedge shaped areas with low signal intensity are
most likely to be chronic prostatitis (Fig. 5A) or other benign
conditions [23].Fig. 5. Multiparamertic MR images showing typical chronic prostatitis features in
topathology. (A) Axial T2WI MR Image shows diffuse low signal intensity of the
demonstrate restricted diffusion with low ADC map (however, compared to previous
and (E) Curve of the DCE image demonstrate early enhancement with retaining
diagnosis of chronic prostatitis. (F) MRS curve and (G) Value of MRS show low
Cho þ Cr/Ci ratio, ruling out prostate cancer and leading to diagnosis of prostatitis.
prostatitis.On T2WI MR Images, the central gland which appears as
low signal intensity is often intermixed with well circum-
scribed heterogeneous high and low signal intensity BPH
nodules (Fig. 1). A thin boundary of hypo-intense pseudo-the peripheral zone of the prostate in a 56 year old man, confirmed by his-
bilateral peripheral zone of prostate. (B) Axial DWI and (C) Axial ADC map
one ADC is not too low), suggestive more of prostatitis. (D) Axial DCE image
the contrast (type II curve), consistent with non-tumorous lesion leading to
peak value of choline and creatine and high peak value of citrate with low
(H) Histopathology slide confirms the inflammatory process confirming chronic
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zone to be well distinguished from it [15]. Due to the het-
erogeneous appearance, the identification of prostate cancer in
the central gland is very challenging and relatively difficult.3.2. T1WI MR imagingThe normal appearance of the prostate on T1WI MR Im-
ages is homogenously iso-intense and the detailed architec-
tural assessment is almost impossible. So this sequence
provides little to no utility in the detection of the suspicious
lesions. However, T1WI MR Images can be used to evaluate
the hemorrhagic foci as this appear as hyper-intense lesions
and also helpful to evaluate nodal involvement.3.3. DWI MR imagingOn DWI MR Images, the normal tissue appears as low
signal intensity or unrestricted due to random Brownian
movement of water molecules. Tissues with high cellular
density but intact cell membranes like cancerous tissue, ab-
scess, fibrosis or cytotoxic edema appear as high signal in-
tensity or restricted due to inability of water molecules to
diffuse freely. Depending on the magnetic field strength and
the b-value, the sensitivity of the DWI MR Images vary.
Apparent diffusion coefficient (ADCs) map, which is inversely
proportional to the degree of diffusion, can be calculated on
the basis of DWI MR Images. Low ADC values, which are
hypo-intense on the ADC map, and high ADC values, which
are hyper-intense on the ADC map, represent tissues with and
without restriction of water diffusion, respectively [24]. The
peripheral zone of prostate is highly rich in fluid filled tubular
tissue owing to homogenously unrestricted diffusion, appear-
ing as low signal intensity on the DWI MR Images and high
ADC values (Fig. 3B and C). The central gland is richer in
compact smooth muscle rather than glandular tissue in com-
parison to the peripheral zone, owing to higher percentage of
intracellular than extracellular fluid [16]. Further, the ADC
values of both the central gland and the peripheral zone in-
crease with age, due to the atrophic changes with ages.
Chronic prostatitis is a condition in which there is inflam-
mation of the gland with extracellular fluid surrounding the
prostatic cells and stromal infiltration of chronic inflammatory
cells particularly lymphocytes, plasma cells, macrophages
[25]. This results in the destruction of the prostate gland
leading to weakening of the water diffusion capability. Due to
this, chronic prostatitis presents with lower ADC values
(Fig. 5B and C) and granulomatous prostatitis can present with
even lower ADC values.
Due to the high cellular density and high nucleus to cyto-
plasm ratio than the normal prostate tissue, and infiltration of
the glandular parenchyma with cancerous cells, the prostate
cancer shows lower ADC values (Fig. 4B and C) relative to the
normal tissue [26]. DWI shows differences between prostatitis
and prostate cancer in both the peripheral zone and central
gland, however, usability in clinical practice is limited as a
result of significant overlap in ADCs [12].BPH, on the other hand, is represented as intermixed areas
of low and high ADC values. This is due to the variable
involvement of the glandular, muscular and stromal elements
with hyperplasia of central glands [27].3.4. DCE MR imagingDynamic contrast enhanced MR examination is based on
the pharmacokinetic properties of tissues in dynamic uptake
and washout of Gadolinium based contrast agent, helping in
the differentiation of tissues based on their functional assess-
ment. During the examination, fast T1WI MR Images are
repeatedly acquired in different phases viz. before, during and
after the injection of the bolus dose (2e4 mL/s) of a Gado-
linium based contrast agent. The preferred temporal resolution
for images acquisition is less than 15s per acquisition with
reason of interest being the prostate and the seminal vesicles
during this examination [18].
The rapid intake of contrast showing enhancement and
subsequently early and pronounced washout demonstrates
increased tumor vascularity in relation to the normal sur-
rounding tissues [28,29] (Fig. 4D and E). In chronic prostatitis,
there is proliferation of blood vessels along with fibrous
connective tissue resulting in increased blood supply. How-
ever, the normal architecture of microcirculation is relatively
maintained [30]. Chronic prostatitis usually shows no to mild
early enhancement as well as late enhancement retaining it till
delay phase [31,32] (Fig 5D and E). On the other hand, the
granulomatous prostatitis demonstrates moderate enhance-
ment, which is usually lower than prostate cancer [33].
However, it has been reported that DCE MR Images has better
diagnostic importance in comparison to T2WI images alone
[34,35].3.5. MR spectroscopic imagingMR spectroscopy is based on the quantitative differences in
the proton precessing frequency of different composing ele-
ments of the tissue. The chemical shift, which is compound-
specific biochemical analysis, occurs due to the compound
specific insulation from Bo. The MR spectroscopy allows
detection of citrate and choline in prostate tissue. Citrate is
present in high level (>60 mM) in normal prostate tissue due
to which the citrate peak is present at a frequency of 2.6 ppm
[36]. The decreased levels are seen in case of chronic pros-
tatitis as well as in prostate cancer. Choline peak is present at a
frequency of 3.2 ppm in normal prostate tissue, however, the
peak is often elevated in case of prostatitis as well as in
prostate cancer [25,37,38]. Creatine, a metabolic byproduct,
peaks at frequency of 3.0 ppm and the level is low in both
normal and prostate cancer without significant difference
[39,40]. Since it is difficult to resolve choline peak from
creatine, both are evaluated together in prostate MR spec-
troscopy. Polyamines, regulating molecules for cell prolifera-
tion and differentiation, peak at frequency of 3.1 ppm
normally and is found to be reduced or absent in prostate
cancer [41]. Cho þ Cr/Ci ratio is calculated both
76 V.K. Sah et al. / Radiology of Infectious Diseases 1 (2015) 70e77quantitatively and qualitatively, on the basis of area under
curve and peak heights respectively [13,18,42]. The prostatitis
(Fig. 5F and G) is highly suggestive if choline plus creatine to
citrate (Cho þ Cr/Ci) ratio is not elevated and the diagnosis of
prostate cancer (Fig. 4F and G) can be ruled out [39,43,44].
4. MR image guided biopsy
TRUS guided biopsies have low detection rate and its
performance can be affected by under sampling and under-
scoring of the cancerous process [45,46]. MR images can be
helpful in obtaining targeted biopsies to rule out lesions sus-
picious for cancer.
5. Summary
Multiparametric MR imaging uses the conventional as well
as the functional MR Imaging sequences acquired in high field
strength of 1.5 T or 3.0 T MR. Multiparametric MR imaging
clearly depicts the normal anatomy of the prostate and dem-
onstrates the morphological characteristics of chronic prosta-
titis and other prostatic disorders. After combining the MR
imaging features of all the sequences, chronic prostatitis can
be more or less differentiated from other prostate pathology. In
case of suspicion for prostate cancer, multiparametric MRI can
be helpful in obtainingtargetedbiopsies of the suspicious lesion
for histo-pathological examination.
In conclusion, multiparametric MRI can be the best imag-
ing modality for the assessment and diagnosis of chronic
prostatitis and its differentiation from prostate cancer.
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